A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

被引：0
作者：
Stanley B. Cohen
Rieke Alten
Hideto Kameda
Tomas Hala
Sebastiao C. Radominski
Muhammad I. Rehman
Ramesh Palaparthy
Karl Schumacher
Susanne Schmitt
Steven Y. Hua
Claudia Ianos
K. Lea Sewell
机构：
[1] Metroplex Clinical Research Center,
[2] Schlosspark-Klinik University Medicine,undefined
[3] Toho University Ohashi Medical Center,undefined
[4] Center for Clinical and Basic Research,undefined
[5] Universidade Federal do Paraná,undefined
[6] Pfizer Inc.,undefined
[7] Pfizer Inc.,undefined
[8] Hexal AG,undefined
[9] Pfizer UK,undefined
[10] Pfizer Inc.,undefined
来源：
Arthritis Research & Therapy | / 20卷
关键词：
Infliximab; PF-06438179/GP1111; Biosimilar; Rheumatoid arthritis; Dose escalation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 17 条
  • [1] A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
    Cohen, Stanley B.
    Alten, Rieke
    Kameda, Hideto
    Hala, Tomas
    Radominski, Sebastiao C.
    Rehman, Muhammad I.
    Palaparthy, Ramesh
    Schumacher, Karl
    Schmitt, Susanne
    Hua, Steven Y.
    Ianos, Claudia
    Sewell, K. Lea
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [2] Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis
    Palaparthy, Rameshraja
    Rehman, Muhammad, I
    von Richter, Oliver
    Yin, Donghua
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 1065 - 1074
  • [3] A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis
    Kameda, Hideto
    Uechi, Eishi
    Atsumi, Tatsuya
    Abud-Mendoza, Carlos
    Kamei, Kazumasa
    Matsumoto, Tsugumi
    de Leon, Dario Ponce
    Rehman, Muhammad, I
    Zhang, Min
    Radominski, Sebastiao C.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (07) : 876 - 881
  • [4] The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product
    McClellan, Joseph E.
    Conlon, Hugh D.
    Bolt, Michael W.
    Katfayan, Vatche
    Palaparthy, Rameshraja
    Rehman, Muhammad, I
    Kirchhoff, Carol F.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [5] A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01)
    Palaparthy, Ramesh
    Udata, Chandrasekhar
    Hua, Steven Y.
    Yin, Donghua
    Cai, Chun-Hua
    Salts, Stephanie
    Rehman, Muhammad I.
    McClellan, Joseph
    Meng, Xu
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (04) : 329 - 336
  • [6] Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
    Alten, Rieke
    Batko, Bogdan
    Hala, Tomas
    Kameda, Hideto
    Radominski, Sebastiao C.
    Tseluyko, Vira
    Babic, Goran
    Cronenberger, Carol
    Hackley, Sarah
    Rehman, Muhammad
    von Richter, Oliver
    Zhang, Min
    Cohen, Stanley
    RMD OPEN, 2019, 5 (01):
  • [7] Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials
    Bae, Sang-Cheol
    Lee, Young Ho
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (05) : 922 - 929
  • [8] A Clinical Trial and Extension Study of Infliximab in Korean Patients with Active Rheumatoid Arthritis despite Methotrexate Treatment
    Kim, Jinhyun
    Ryu, Heejung
    Yoo, Dae-Hyun
    Park, Sung-Hwan
    Song, Gwan-Gyu
    Park, Won
    Cho, Chul-Soo
    Song, Yeong-Wook
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (12) : 1716 - 1722
  • [9] A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis
    Burmester, Gerd
    Chien, David
    Chow, Vincent
    Gessner, Melissa
    Pan, Jean
    Cohen, Stanley
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (08): : 1003 - 1014
  • [10] A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate
    Matsuno, Hiroaki
    Matsubara, Tsukasa
    MODERN RHEUMATOLOGY, 2019, 29 (06) : 919 - 927
12